Cadence HypertensionOS: De-Risking AI for Billions in Cardiac Health
The whole field of cardiovascular AI is splitting into two camps. You’ve got your generalized, consumer-facing apps, and…
FDA TEMPO Pilot: De-Risking Digital Health for Investors
There’s a constant tug-of-war in digital health, especially in cardiology: tech moves at light speed, but clinical validation…
Cadence’s Remote Cardiac AI: Proven Clinical ROI for Investors
The field of cardiovascular AI is changing how we handle diagnostics, monitoring, and therapy. But if you’re working…
Cleerly’s AI: De-Risking CCTA for Investors and Clinicians
The world of cardiovascular AI is producing new diagnostic tools at a breakneck pace, but getting them through…
FDA Breakthrough vs. Clearance: De-Risking Cardiac AI Investments
The money pouring into cardiovascular AI is staggering, and for good reason, the tech promises real, far-reaching clinical…
Smartwatch vs. Medical ECG: De-risking Cardiac AI Investments
Take AliveCor’s Kardia devices. They let someone record a medical-grade ECG on a small, portable device by capturing…
Cardiac AI: Top FDA Clearances & Why They Matter for Investors
The diagnostic cardiac AI field is exploding, fired up by new tech and a serious need for better,…
JAHA Publication: Cardiac AI’s Billion Dollar Validation Gate
The burgeoning landscape of artificial intelligence in cardiology promises a revolution in patient care, from early detection to…
Cardiac AI: Unlocking Billion-Dollar Value in Cardiovascular Health
We’re drowning in cardiovascular data, from high-resolution imaging and continuous physiological monitoring to complete genomic sequencing, and we…
Cardiac AI: Why Specialized Models Trump General LLMs for Safety
The burgeoning landscape of artificial intelligence in healthcare presents a critical dichotomy: the broad, generalist capabilities of large…